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Background: Seasonal Allergic Rhinitis Caused by Japanese Cedar Pollinosis (SAR-JCP) is a most common
allergic rhinitis, affecting about 40% in Japan, but the inﬂuence from SAR-JCP upon asthma is contro-
versial. The purpose of this study is to investigate the effect of coexistence of SAR-JCP upon control status
of asthma using SACRA (Self-Assessment of Allergic Rhinitis and Asthma Questionnaire).
Methods: The design was prospective, single-center, observational study. Asthmatic patients were clas-
siﬁed into 3 groups, patients without rhinitis, those with perennial rhinitis or those with SAR-JCP from
the results of SACRA. The control status of asthma were evaluated by Visual Analog Scale (VAS) in SACRA
and Asthma Control Test (ACT) score. They were evaluated twice, from September to January (nonpollen-
season) and February to April (pollen-season) and compared.
Results: 451 patients were enrolled and 325 cases (72%) were diagnosed as having comorbidity of
rhinitis, among which 173 with only perennial rhinitis, while 152 with SAR-JCP. There was no signiﬁcant
difference in asthma control level measured by VAS and ACT score among 3 groups during nonpollen-
season. The asthma control level measured by VAS (1.91e2.95) and ACT score (22.7e21.6) got worse
during pollen-season among patients with SAR-JCP, even though 84% received treatment for rhinitis.
Although it differed according to criteria, asthma control during pollen-season was impaired in 18e38%
asthmatic patients with SAR-JCP.
Conclusion: It is possible to minimize the inﬂuence of AR on asthma control by obtaining an accurate
diagnosis and providing sufﬁcient treatment for rhinitis.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Asthma and allergic rhinitis (AR) are common health problems
that cause major illness worldwide. Several studies have shown
that rates for asthma vary from one country to another and there
are more than 300 million asthmatics worldwide.1 The prevalence
of AR is estimated to range from 10 to 30% in the United States andedicine, National Center for
, Tokyo 162-8655, Japan.
).
ety of Allergology.
rgology. Production and hosting by ElsEuropean countries.2e4 Using conservative estimate, it is proposed
that AR occurs in approximately 500 million people and about 200
million people also have asthma as a comorbidity.5,6
According to the epidemiological survey in Japan, the preva-
lence of AR in general population was 39.4%, extremely high level
compared with those in other developed countries. Seasonal
allergic rhinitis caused by Japanese cedar pollinosis (SAR-JCP), a
disease unique to Japan, showed a prevalence of 26.5%, accounting
for majority of AR cases.7,8 Furthermore, according to cross-
sectional nation-wide surveillance in Japan, SACRA (State of the
Impact of Allergic Rhinitis on Asthma Control) study,9 rhinitis was
present in 67.3% of asthmatics and asthma control was signiﬁcantly
impaired in patients with rhinitis.evier B.V. All rights reserved.
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and, because of their large size, do not reach the lower respiratory
tract and were therefore considered unlikely to cause asthma. As a
result, only perennial AR was suspected to be strongly related to
asthma aggravation, whereas reports on seasonal rhinitis-induced
aggravation of asthma were limited.10 However, with the growing
awareness in recent years that airborne orbicles (particle size
approx. 1 mm) on the surfaces of cedar pollen grains are widely
disseminated, their relationship to asthma has been attracting
attention, and there are now sporadic reports suggesting SAR-JCP-
induced aggravation of asthma.11,12 However, inﬂuence of SAR-JCP
on asthma control is still controversial.
The purpose of this study is to investigate the effect of coexis-
tence of SAR-JCP upon asthma control status receiving long-term
controller medications. We have reported clinical usefulness of
SACRA (Self-Assessment of Allergic Rhinitis and Asthma Ques-
tionnaire), which GINA and ARIA Japan Committees developed in
2011, a simple guideline-based tool to evaluate the severity of both
diseases.13 In this study, control status of asthmawere evaluated by
Visual Analog Scale (VAS), GINA asthma control criteria in SACRA,
and Asthma Control Test (ACT) score.
Methods
Subjects and study design
The subjects of the study were outpatients of the National
Center for Global Health and Medicine, aged 20 years or older, with
asthma who had been treated with controller medication for more
than 6 months. The diagnosis of asthma was deﬁned as the
presence of compatible clinical history and pulmonary function
tests demonstrating variable airﬂow limitation by means ofTable 1
Demographic characteristics of all patients at ﬁrst surveillance.
All subjects Aller
Patients, number 451 126
Age
Mean ± SD (y.o.) 56.9 ± 16.7 61.6
60 years old 226 76
<60 years old 225 50
Sex
Male 196 62
Female 255 64
Asthma duration (y) 14.3 ± 13.4 12.6
FEV1.0 (L) 2.19 ± 0.78 2.10
FEV1.0% (%) 71.9 ± 12.3 70.0
Total IgE (IU/mL) 602.3 ± 2034 531.8
Serum eosinophil 311.8 ± 369.6 193.4
GINA treatment step
Step 2 63 19
Step 3 102 35
Step 4 251 67
Step 5 35 5
Asthma treatment
ICS/LABA 314 (69.6%) 85 (6
LTRA for asthma (A) 195 (43.2%) 37 (2
Treatment for rhinitis (B) 194 (43%) 13 (1
A or B 298 (66.1%) 47 (3
ACT score 22.08
Asthma VAS 1.78
Rhinitis VAS 0.79
FeNO (ppb) 35.7
GINA control status
Well controlled 103 (
Partly controlled 19 (1
Uncontrolled 4 (3.1
Data are presented as mean ± SD. p values of chi-square test (*) and ManneWhitney U-
y Revealed statistically signiﬁcant.bronchodilator responsiveness or by demonstrating bronchial-
hyperresponsiveness using methacholine challenge, which satis-
ﬁed those of GINA.14 In order to exclude the inﬂuence of upper
airway inﬂammation on the symptoms of rhinitis and asthma,
patients complaining of fever and/or pharyngeal pain were
excluded from the survey. These patients were to be surveyed only
after these symptoms had shown amelioration.
The study design was prospective, single-center, observational
study. Asthmatics from whom written consent was obtained were
included in the study. During a routine examination, the patients
were asked to take ACT survey (asthma control status for only the
previous one week; ACT originally inquired for the past 4 weeks).
Fractional exhaled nitric oxide (FeNO) value was measured using
NIOX-MINO (Aerocrine Ltd., Solna, Sweden).15 Thereafter patients
were asked to ﬁll out SACRA in the presence of physician. We have
already reported the content of SACRA in detail.13 In short, asthma
control questionnaire consisted of questions about symptoms
(qualitative) in the past one week to assess the asthma control level
as speciﬁed by GINA and visual analog scale (VAS) (quantitative),
which ranged from not at all bothersome (0) to extremely bother-
some (10). AR symptomswere also evaluated quantitatively by VAS.
After the entries were checked, blood tests (eosinophil count and
IgE RAST) were performed. Antigen-speciﬁc IgE measured were as
follows; house dust, Dermatophagoides, Japanese ceder, cypress,
ragweed, Japanese mugwort, orchard grass, fungi (Aspergillus,
Candida) and pets (dog, cat).
The ﬁrst survey was carried out nonpollen scattering season
from September 2011 to January 2012. Strictly to say, September to
January is non-Japanese cedar pollen scattering season, because
Grass pollen is dispersed from June to October, while weeds pollen
dispersed from August to October in Japan. In this study, however,
we dare describe this period as nonpollen season, because thegic rhinitis () Allergic rhinitis (þ) p Value
325
± 117.1 55.2 ± 16.2 <0.01y
150 0.02*,y
175
134 0.01*,y
191
± 12.9 15.1 ± 13.6 0.07y
± 0.82 2.25 ± 0.78 0.02y
± 10.9 72.9 ± 12.3 0.01y
± 2386 661.2 ± 1809 0.53
± 337.5 399.8 ± 404 <0.01y
44 0.05*,y
67
184
30
7.5%) 229 (70.5%) 0.88
9.45) 158 (48.6%) 0.03y
0.3%) 182 (56%) <0.01y
7%) 251 (77%) <0.01y
± 3.67 22.51 ± 3.16 0.57
± 2.34 1.96 ± 2.36 0.21
± 1.59 4.03 ± 3.26 <0.01y
± 25.8 42.6 ± 36.7 0.03y
81.8%) 263 (80.9%)
5.1%) 46 (14.2%) 0.08*
%) 16 (4.9%)
test are shown.
Fig. 1. Asthma control level measured by VAS during nonpollen scattering season
based upon GINA treatment step (asthma severity) at ﬁrst surveillance. * Revealed
statistically signiﬁcant with Cochran and Cox analysis.
Table 2
Demographic characteristics of patients with allergic rhinitis at ﬁrst surveillance.
Perennial
rhinitis only
SAR-JCP
(þ/ perennial rhinitis)
p Value
Patients, number 173 152
Age
Mean ± SD (y.o.) 56.3 ± 16.9 53.9 ± 15.3 0.09
60 years old 84 66 0.35*
<60 years old 89 86
Sex
Male 66 68 0.23*
Female 107 84
Asthma duration (y) 13.8 ± 13.6 16.7 ± 13.6 0.03y
FEV1.0 (L) 2.22 ± 0.74 2.28 ± 0.81 0.26
FEV1.0% (%) 73.9 ± 11.3 71.8 ± 13.3 0.07
Total IgE (IU/mL) 712.9 ± 2222 602.3 ± 1180 0.29
Serum eosinophil 338.9 ± 397.4 340.8 ± 413.2 0.48
GINA treatment step
Step 2 30 14 0.04*,y
Step 3 41 26
Step 4 93 91
Step 5 9 21
Asthma treatment
ICS/LABA 109 (63%) 120 (78.9%) <0.01y
LTRA for asthma (A) 75 (43.3%) 83 (54.6%) 0.04y
Treatment for
rhinitis (B)
87 (50.3%) 95 (62.5%) 0.03y
A or B 123 (71%) 128 (84%) 0.01y
Data are resented as mean ± SD. p values of chi-square test (*) and ManneWhitney
U-test are shown.
y Revealed statistically signiﬁcant.
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pollen. The diagnosis of AR was made mainly based on rhinitis
symptoms reported on SACRA and serum allergen-speciﬁc IgE RAST
as a reference to Japanese diagnostic criteria for AR.7,16 The patients
diagnosed as SAR-JCP with IgE positive for Japanese cedar received
another survey during pollen-season February to April 2013, and
the results of SACRA, ACT scores were compared with those ob-
tained during nonpollen-season.
Statistical analysis
All measurement values were presented as mean ± standard
deviation (SD). The chi-square tests and ManneWhitney U-tests
were analyzed to compare each group. Comparisons between each
measured values during nonpollen and pollen season were
analyzed using paired Student t-test, and McNemar test. The cor-
relation between 2 parameters such as VAS and ACT score was
analyzed by the Pearson correlation coefﬁcient method. Logistic
regression analysis was performed to explore the multivariate odds
ratios between risk factors and outcomes of interest.
Performance of this study was approved by the Ethics Com-
mittee of the National Center for Global Health and Medicine
(NCGM-G-001108-00). Clinical trial registration number was
UMIN000012457. Use of SACRA questionnaire, and translation in
English of Japanese original version were approved by GINA and
ARIA Japan committee.
Results
Subjects and background
From 462 patients surveyed, valid responses were obtained
from 451 patients. This included 196 males and 255 females, with a
mean age of 56.9 years old, and FEV1.0% 71.9%. Asthma treatment
included leukotriene receptor antagonists (LTRA) in 195 patients.
There were 194 patients already receiving some treatment, either
oral or nasal drugs, for AR (Table 1).
Prevalence of AR and its impact upon asthma control during
nonpollen-season
The AR comorbidity rate based upon the previously mentioned
criteria, was 72% (325 patients). As shown in Table 1, the mean age
of asthmatic patients with comorbid ARwas signiﬁcantly lower and
there were more females as compared with those free of comorbid
AR. Judging from the GINA treatment step, severely asthmatics
receiving intensive treatments were signiﬁcantly more numerous
among those with comorbid AR. In the group with comorbid AR,
LTRA was prescribed as asthma medication to 158 patients (48.6%)
and, if these patients were included, 251 (77%) had already been
given some form of treatment for AR. The ﬁrst survey conducted
during nonpollen-season had shown a relatively favorable level of
asthma control, with the overall mean ACT score being 22.3 and
GINA asthma control level of “well controlled” in 366 patients.
Furthermore, no signiﬁcant difference was observed between the
groups with and without comorbid AR n any of the following
evaluation criteria: ACT score, asthma VAS, and GINA asthma con-
trol level. Only FeNO was signiﬁcantly higher in the group with
comorbid AR than in the group without comorbid AR. When pa-
tients were classiﬁed by GINA treatment step into 2 subgroups, i.e.,
the mild asthma subgroup in steps 2 to 3 and the moderate to se-
vere subgroup in steps 4 to 5, no signiﬁcant difference was
observed in asthma VAS between patients with versus without
comorbid AR in mild subgroup. In moderate to severe subgroup, in
contrast, the asthma VAS was signiﬁcantly higher in the group withcomorbid AR than in the group without comorbid AR, showing a
tendency for poorer asthma control in the former group (Fig. 1).Prevalence of SAR-JCP and its impact upon asthma control
When patients with comorbid AR were assessed for SAR-JCP
based on results of IgE RAST and on symptom aggravation during
pollen-dissemination season, 173 patients (38.4% of all patients)
were found to have perennial AR only, whereas 152 (33.7%) had
SAR-JCP either with (n ¼ 53) or without perennial AR (n ¼ 99). In
addition to SAR-JCP, there were small number of other pollinois.
Forty-ﬁve patients were IgE positive for ragweed, 55 cases positive
for Japanese mugwort and 59 cases positive for orchard grass. For
example, among 59 patients IgE positive for orchard grass, 57 cases
were simultaneously IgE positive for Japanese cedar, while other 2
cases were IgE positive for house dust, and there were no cases IgE
Table 3
Change of control status of asthma and allergic rhinitis between 2 surveillances
among the patients with comorbid AR.
Non pollen
scattering season
Pollen scattering
season
p Value
ACT score 22.7 ± 3.05 21.6 ± 3.89 <0.01
Asthma VAS 1.91 ± 2.32 2.95 ± 2.48 <0.01
Rhinitis VAS 2.72 ± 3.33 3.73 ± 2.68 0.04
FeNO (ppb) 45.3 ± 36.7 43.1 ± 35.9 0.14
GINA control status
Well controlled 123 (80.9%) 109 (71.7%) 0.16*
Partly controlled 18 (11.8%) 28 (18.4%)
Uncontrolled 11 (7.3%) 15 (9.9%)
Data are presented as mean ± SD. p values of McNemar test (*) and ManneWhitney
U-test are shown.
Fig. 2. The change of asthma VAS value and ACT score from nonpollen season to pollen
season. The differences in ACT score or asthma VAS between the pollen season and the
non-pollen season are deﬁned as DACT and DVAS, respectively. For both parameters,
any degree of aggravation, i.e., DACT <0 and/or DVAS >0, is deﬁned as “lax criteria for
aggravation”, 58 patients (38.2%) met these criteria, while ACT 2 and VAS 100 is
deﬁned as “more strict criteria for aggravation,” 39 patients (25.7%) met these criteria.
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follows; 2 cases perennial rhinitis only, 15 cases only SAR-JCP, and
42 cases both SAR-JCP and perennial rhinitis.
The second survey was conducted in these 152 patients during
pollen-season. As shown in Table 2, no difference was observed in
either age or sex between patients with andwithout comorbid SAR-
JCP, in those with comorbid AR. The only difference was a higher
percentage of patients with severe asthma in the group with co-
morbid SAR-JCP, as judged by the GINA treatment step. AR therapy
of any type, including LTRA prescribed for asthma, had already been
administered to as many as 123 patients (71%) with comorbid
perennial AR only, but the number of treated patients was signiﬁ-
cantly greater, 128 (84%), in the group with comorbid SAR-JCP.
During nonpollen-season, no signiﬁcant difference was
observed in asthma control levels, as measured by VAS and ACT
scores, among the groups without comorbid AR, with perennial AR,
andwith SAR-JCP. During pollen-season, in contrast, the groupwith
comorbid SAR-JCP showed an overall tendency for poor asthma
control, with a signiﬁcant decrease in the ACT score from 22.7 to
21.6 and a signiﬁcant increase in the asthma VAS from 1.91 to 2.95
(Table 3).
Regarding the correlation between asthma VAS and rhinitis VAS,
the Pearson correlation coefﬁcient (r) was 0.2759 in the group
without comorbid AR and 0.2212 in the group with perennial AR,
showing no correlation in either group. In the groupwith comorbid
SAR-JCP, in contrast, r was 0.2611 during nonpollen-season but
increased to 0.4252 during pollen-season, showing a correlation
(p ¼ 0.03), and thereby suggesting the aggravation of rhinitis
symptoms to exert an inﬂuence on theworsening of asthma control
(Table 4).Worsening of asthma control in patients with comorbid SAR-JCP
during pollen-season
The inﬂuence of SAR-JCP on asthma control in individual pa-
tients was investigated. GINA asthma control level decreased fromTable 4
Correlation of between VAS, ACT score and FeNO value in each sub-groups.
Allergic rhinitis () Perennial rhin
Asthma VAS vs ACT score 0.72436y 0.69621y
Asthma VAS vs Rhinitis VAS 0.27588 0.22118
Asthma VAS vs FeNO 0.16251 0.03591
Rhinitis VAS vs FeNO 0.04129 0.10671
The Pearson correlation coefﬁcient value (r) are shown.
y Revealed statistically signiﬁcant.“well controlled” during nonpollen-season to “partly controlled/
uncontrolled” during pollen-season in 28 patients (18%).
The differences in ACT score or asthma VAS between pollen-
season and nonpollen-season are deﬁned as DACT and DVAS,
respectively. For both parameters, any degree of aggravation during
nonpollen-season, i.e., DACT <0 and/or DVAS >0, is deﬁned as “lax
criteria for aggravation”. We found that 58 patients (38%) met these
criteria. On the other hand, in the assessment of ACT scores over
time, clinically signiﬁcant differences in the scorewere reportedly 2
to 3.17 If “ACT 2 and VAS 1” is deﬁned as “more strict criteria for
aggravation,” 39 patients (26%) in our survey met these criteria
(Fig. 2). Thus, 18%e38% of asthmatics with comorbid SAR-JCP
showed a worsening of asthma control during pollen-season,
depending on the method of the assessment.
Factors related to a worsening of asthma control during pollen-
season among the group with “more strict criteria for aggravation”
were investigated employing multivariate analysis. As shown in
Table 5, lack of comorbid perennial AR and the occurrence of nasal
congestion symptoms were identiﬁed as signiﬁcant factors.Discussion
We investigated the inﬂuence of rhinitis symptoms on asthma
control in asthmatics with comorbid AR using the SACRA and ob-
tained the following ﬁndings: (i) Seventy-two percent of asth-
matics have comorbid AR of some type, and 34% have comorbid
SAR-JCP, (ii) during nonpollen-season, comorbid AR has no effect
on asthma control, not only in patients with comorbid SAR-JCP but
also in those with perennial AR, provided that asthma and rhinitis
are appropriately treated, whereas during pollen-season, asthma
control worsens in patients with comorbid SAR-JCP, and (iii)itis SAR-JCP
Non pollen scattering season Pollen scattering season
0.72618y 0.64754y
0.26111 0.42515y
0.09271 0.07509
0.03584 0.03627
Table 5
Contributory factors for the asthma exacerbations during pollen season among the
patients with comorbid SAR-JCP; results of multivariate logistic regression analysis.
Factors p Value Hazard ratio 95% CI
Sex; female 0.98 0.926 0.446e1.923
Age; < 60 years old 0.93 1.036 0.501e2.144
FEV1.0; < 70% 0.48 1.394 0.669e2.911
GINA step 2 or 3 0.92 0.954 0.415e2.191
GINA step 5 0.95 0.892 0.304e2.619
Without perennial rhinitis 0.03y 2.564 1.081e6.082
LTRA for asthma 0.65 1.269 0.608e2.654
Yearly anti-allergic drug 0.11 0.326 0.092e1.154
Nasal corticosteroid use 0.66 0.788 0.374e1.658
Nasal obstruction 0.03y 2.362 1.126e4.956
Watery discharge 0.21 1.714 0.823e3.569
y Revealed statistically signiﬁcant.
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symptoms in 18e38% of patients with comorbid SAR-JCP, and in
particular, exacerbation of nasal congestion correlates signiﬁcantly
with a worsening of asthma control.
According to the above-mentioned SACRA study9 and to others,
AR comorbidity rate in asthmatics in Japan is approximately 65%,
whereas the prevalence of AR was observed to be slightly higher in
our study. However, given that patients examined by primary care
physicians are the main targets of most epidemiological surveys,
whereas patients with relatively severe disease treated in tertiary
care medical institutions were the targets of our study, the preva-
lence of 72% can be regarded as clinically reasonable. The SAR-JCP
comorbidity rate of 33.7% is not signiﬁcantly different from the
rates in other reports on asthmatic patients in Japan.18e20 Previ-
ously, we reported a strong correlation between VAS and the ACT
score during nonpollen season.13 In the preset study, we analyzed
subgroups classiﬁed by the presence or absence of comorbid AR
and based on the presence or absence of pollen dissemination, and
observed strong correlations between these two parameters in all
subgroups studied. These results conﬁrm the usefulness of the
asthma VAS as an index for assessing asthma control.
In our study, comorbid AR did not inﬂuence asthma control
during nonpollen-season. This observation differs from those
described in previous reports which showed aworsening of asthma
control in patients with comorbid AR. There are several possible
reasons for this discrepancy. First, SACRA and other studies
included the pollinosis season in the study period, whereas in our
study, seasonal factors were strictly separated when making com-
parisons. Second, patients with comorbid AR had already received
more intensive treatment for asthma than those without comorbid
AR, as judged by the GINA treatment step. Third, most of our target
patients had already achieved favorable asthma control, solely as a
result of receiving adequate treatments for asthma and rhinitis.
Regarding asthma control in our study, the rate of partly
controlled/uncontrolled was 18.6%. A recent survey in Japan that
reported that 61% of asthma patients had symptoms in the prior
one month,21 which suggests good asthma control in our patients.
In addition, mean asthma VAS value in the groupwithout comorbid
AR was 1.78, and in the group with comorbid AR, it was 1.96. In the
SACRA study, the mean was 2.90 in the group without and 4.75 in
the group with comorbid rhinitis. From this perspective as well,
asthma control in the present patients can be judged as relatively
good. Several reasons for this may be considered. All the attending
physicians in this clinical study were certiﬁed specialists of aller-
gology. Compared to the situation in the SACRA study where 86% of
patients were examined by a general physician, our study hadmore
specialists involved in diagnosis and treatment, in which LTRA had
already been prescribed to 48% of the patients and 56% receivedsome type of rhinitis treatment may have been a substantial factor
in having achieved good asthma control. This fact suggests the
importance of comorbid AR and its treatment for asthma control.
However, the sub-analysis of patients with moderate to severe
asthma showed a worsening of asthma control in those with co-
morbid AR, suggesting that there was a limit to the efﬁcacy of
aggressive rhinitis treatment in patients with severe asthma.
Among causes of pollen-induced seasonal asthma, ragweed-
induced asthma is frequently observed in the United States and
some other countries and, in this type of asthma, the local treat-
ment of rhinitis alone is reported to be effective for improving
asthma control.22 Thus, the close relationship between rhinitis and
asthma is well known. In contrast, SAR-JCP has been considered
unlikely to be related to the occurrence and aggravation of asthma,
despite the far greater quantities of pollen grains being dissemi-
nated as compared with ragweed. Attention has only recently been
paid to the relationship between cedar pollinosis and asthma, and
there are sporadic reports indicating that asthma symptoms
worsenwith the aggravation of rhinitis symptoms in approximately
one third of asthmatic patients with comorbid SAR-JCP, but these
reports were based on the results of general questionnaire surveys
only.11,18 In our study, we evaluated asthma symptom aggravation
using a combination of the SACRA prepared based on GINA and
ARIA, and ACT which is widely used clinically. For ACT (25 full
score), the cut-off level of 2e3 has been established for diagnosing
clinical worsening, whereas no such cut-off level has been estab-
lished for VAS. Therefore, we directly applied the percent change at
the cut-off ACT score to VAS (full score 10) for the sake of conve-
nience, and obtained a score of 1 as the cut-off level for VAS.
Although the appropriateness of this method for determining the
cut-off level of VAS requires further validation, the assessment of
asthma control using these two quantitative parameters is
considered to be highly reliable. In our study, asthma symptoms
worsened with the aggravation of rhinitis symptoms in 18%e38% of
patients, depending on the method of evaluation. This aggravation
rate, which was observed under the situations in which 128 pa-
tients (84%) among those with comorbid SAR-JCP were considered
to be receiving some form of treatment for rhinitis, suggests the
presence of a substantial impact of SAR-JCP on asthma control.
Furthermore, the ﬁnding that aggravation of nasal congestion
among rhinitis symptoms correlated signiﬁcantly with asthma
aggravation suggests the importance of more aggressive treatment
for rhinitis, particularly for nasal congestion symptom. The fact that
lack of comorbid perennial AR signiﬁcantly related to a worsening
of asthma control during pollen-season among SAR-JCP patients
also suggest the importance of more aggressive treatment for
rhinitis even during non-pollen-season, because 46 cases out of 53
patients with SAR-JCP with perennial rhinitis already received
LTRA, while 37 out of 99 patients with only SAR-JCP received LTRA.
A limitation of the present study is that it was conducted only in
the limited number of patients in a single medical institution. On
the other hand, this resulted in studying a relatively homogeneous
patient population receiving essentially identical levels of treat-
ment from specialists, allowing investigation based on detailed
information not available in most epidemiological surveys. The
results demonstrated that, in asthmatic patients with comorbid AR,
it is possible to minimize the inﬂuence of AR on asthma control by
obtaining an accurate diagnosis and providing sufﬁcient treatment
for rhinitis. We believe that diagnosis and treatment of AR, espe-
cially SAR-JCP can greatly contribute to improved quality of asthma
management and improved QOL in asthmatics.Authors' contributions
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